Imcyse
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- $59M
Investors
- 8
About Imcyse
Based in Liege, Belgium, and founded in 2011, Imcyse SA provides therapies for severe, chronic autoimmune diseases.U. Leuven Research & Development, Noshaq, SFPI-FPIM, and Société Régionale d'Investissement de Wallonie. As of 2024, Denis Bedoret is the Chief Executive Officer (CEO) of the company. Imcyse SA provides the Imotope platform, designed to prevent, halt, and potentially cure autoimmune diseases. The company's platform generates cytolytic T cells that specifically target and eliminate abnormal disease pathways without adversely affecting the overall immune system. Imotopes is a small and irregular peptide injections, that prompt an immune response and obstruct autoimmune pathways.
Who invested in Imcyse
8 investors across 2 rounds
See all investors in Imcyse
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Imcyse
Who invested in Imcyse?
Imcyse has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Imcyse raised?
Imcyse has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Imcyse last raise money?
Imcyse's most recent round on record is a Series B, in Mar 2021.
What does Imcyse do?
Based in Liege, Belgium, and founded in 2011, Imcyse SA provides therapies for severe, chronic autoimmune diseases.
Where is Imcyse headquartered?
Imcyse is headquartered in Belgium.
Which VCs invest in companies like Imcyse?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Imcyse's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Imcyse? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.